Logo

SDGR

Schrödinger, Inc.

SDGR

Schrödinger, Inc. • NASDAQ
$17.56 ▲ 0.80% (+0.14)
Market Cap $1.29 B
52w High $28.47
52w Low $15.99
Dividend Yield 0%
P/E -7.32
Volume 380.99K
Outstanding Shares 73.66M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $54.324M ▼ $73.986M ▼ $-32.795M ▲ -60.369% ▲ $-0.45 ▲ $-31.168M ▲
Q2-2025 $54.759M ▼ $79.061M ▼ $-43.173M ▲ -78.842% ▲ $-0.59 ▲ $-41.355M ▲
Q1-2025 $59.551M ▼ $82.013M ▼ $-59.808M ▼ -100.432% ▼ $-0.82 ▼ $-49.3M ▼
Q4-2024 $88.317M ▲ $84.842M ▼ $-40.216M ▼ -45.536% ▲ $-0.55 ▼ $-18.948M ▲
Q3-2024 $35.29M $86.15M $-38.136M -108.065% $-0.52 $-66.864M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $400.986M ▼ $653.66M ▼ $332.308M ▼ $321.352M ▼
Q2-2025 $450.185M ▼ $688.244M ▼ $345.372M ▼ $342.872M ▼
Q1-2025 $500.298M ▲ $743.032M ▼ $369.528M ▼ $373.504M ▼
Q4-2024 $352.124M ▼ $823.226M ▲ $401.781M ▲ $421.445M ▼
Q3-2024 $388.679M $669.296M $219.871M $449.425M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-32.795M ▲ $-61.873M ▼ $11.459M ▲ $307K ▼ $-50.107M ▲ $-62.364M ▼
Q2-2025 $-43.173M ▲ $-52.198M ▼ $-55.601M ▼ $2.018M ▲ $-105.781M ▼ $-52.512M ▼
Q1-2025 $-59.808M ▼ $144.063M ▲ $30.632M ▲ $409K ▲ $175.104M ▲ $143.467M ▲
Q4-2024 $-40.216M ▼ $-31.113M ▲ $23.475M ▼ $119K ▼ $-7.519M ▼ $-31.986M ▲
Q3-2024 $-38.136M $-33.256M $90.704M $392K $57.84M $-34.598M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Hosted Software
Hosted Software
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Maintenance
Maintenance
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
On Premise Software
On Premise Software
 $10.00M ▲$30.00M ▲$20.00M ▼$20.00M ▲
Professional Services
Professional Services
 $0 ▲$0 ▲$0 ▲$0 ▲
Revenue From Contract With Customer Before Contribution
Revenue From Contract With Customer Before Contribution
 $30.00M ▲$40.00M ▲$40.00M ▲$40.00M ▲
Software Contribution
Software Contribution
 $0 ▲$0 ▲$0 ▲$0 ▲
Software Products And Services
Software Products And Services
 $30.00M ▲$50.00M ▲$40.00M ▼$40.00M ▲
Contribution
Contribution
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily but not explosively, which is typical for a specialized software-and-collaboration business in pharma and biotech. Gross profitability looks healthy, suggesting the core software and collaboration model can be attractive once scaled. However, operating expenses, especially around research, development, and commercial build-out, are high enough that the company has reported sizable operating losses for most of the past five years. The one year of bottom-line profitability stands out as an exception rather than a trend and likely reflects one-off items or unusually strong partnership revenue. Overall, the income statement tells a story of a company still very much in investment mode, prioritizing growth and scientific progress over near‑term profits, with earnings likely to remain volatile as milestone and collaboration revenues ebb and flow.

Balance Sheet

Balance Sheet The balance sheet shows a solid, though not oversized, base of assets and a meaningful cash position, which provides some cushion to support ongoing losses and research efforts. Debt has increased over time but remains at a level that still appears manageable relative to the overall size of the business, though it does reduce future flexibility if losses persist. Shareholders’ equity has moved down more recently, reflecting cumulative losses after a period when it was higher, which is typical for a company funding substantial R&D. In sum, the balance sheet still offers room to execute the current strategy, but it depends on keeping cash burn under control or reinforcing the capital base through future financing or deeper partnerships over time.

Cash Flow

Cash Flow Cash flows highlight the core financial challenge: the business consistently spends more cash than it generates. Operating cash flow has been negative in most recent years, driven by high research and operating costs relative to current revenue. Capital spending is modest, so the bulk of cash use is not on buildings or equipment but on people, science, and software. As a result, free cash flow is clearly negative, which means the company relies on its existing cash reserves, collaboration inflows, and potential future capital raises to fund operations. The sustainability of this pattern depends on how quickly revenue grows, how efficiently costs are managed, and whether higher-margin software and milestone revenue can scale to offset ongoing R&D.

Competitive Edge

Competitive Edge Schrödinger occupies a differentiated niche at the intersection of computational chemistry, AI, and drug discovery. Its physics-based engine and tools like FEP+ give it a scientific depth that many newer, purely AI-focused competitors may lack, and its long operating history builds credibility with large pharma clients. The integrated software platform, including collaboration tools like LiveDesign, is embedded into customer workflows, creating switching costs and helping sustain relationships with major pharmaceutical and biotech firms. At the same time, the competitive field is crowded and moving quickly: many players are combining AI with wet-lab capabilities, and customers often test multiple platforms. Schrödinger’s competitive strength therefore depends on continuing to demonstrate superior predictive performance, deepening customer integration, and proving that its approach delivers better, faster drug candidates in practice, not just in theory.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the Schrödinger story. The company has spent decades building a physics-based engine and is now layering in AI and machine learning to accelerate design and optimization of drug candidates. Its technology is not just sold as software; it also underpins an internal drug pipeline, which, if successful in clinical trials, would both generate direct value and strongly validate the platform. Programs in oncology and other serious diseases are still early and carry high scientific and regulatory risk, so results may be uneven and take years to fully materialize. Schrödinger is also pushing into areas like predictive toxicology and biologics, widening the scope of its platform. This sustained, broad R&D push explains the current losses but also represents the main potential upside if the science translates into meaningful clinical and commercial outcomes.

Summary

Schrödinger is a high-science, high-investment company: revenue is growing but not yet at a scale to cover its substantial R&D and operating costs, leading to persistent losses and ongoing cash burn. The balance sheet and cash position provide some runway, but the business model assumes that future growth in software, collaborations, and potential drug royalties or commercialization will eventually outweigh today’s spending. Competitively, the company stands out through its deep physics-based platform, strong pharma relationships, and integrated tools, yet it operates in a fast-moving, crowded field where many are chasing similar opportunities with different technologies. The central uncertainty is execution: can Schrödinger turn its technical edge and internal pipeline into durable, diversified revenue streams before cash constraints or competitive pressures bite? For now, the story remains that of a scientifically ambitious platform company trading near-term financial comfort for the chance at longer-term, higher-impact outcomes.

NEWS

November 6, 2025 · 8:30 AM UTC

Schrödinger to Present at Jefferies London Healthcare Conference

Read more

November 5, 2025 · 4:05 PM UTC

Schrödinger Reports Third Quarter 2025 Financial Results

Read more

October 30, 2025 · 7:30 AM UTC

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Read more

October 22, 2025 · 8:30 AM UTC

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Read more

October 15, 2025 · 8:30 AM UTC

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more